Bleeding disorders constitute a large proportion of referrals to hematology departments. Worldwide, acquired causes of bleeding are commoner than inherited ones. To identify the spectrum of these disorders, we evaluated all referrals for bleeding encountered in this tertiary care centre over a one-year period. Of the total 1342 cases, 1040 (77.5%) had underlying exclusively acquired causes, whereas inherited causes constituted 302 cases (22.5%). Amongst acquired causes, disseminated intravascular coagulation was seen in 297 (28.6%), hepatic coagulopathy in 218 (20.9%), neurosurgical causes (intracranial bleeds) in 154 (14.8%), malignancy in 89 (8.6%), and miscellaneous multiple acquired causes including those due to anticoagulant drug overdose in 282 patients (27.1%). Referrals for isolated prolonged prothrombin time or thrombocytopenia were common, but were excluded from this study because not all presented with bleeding. Prompt laboratory work-up and precise identification of acquired causes of bleeding is the key to planning appropriate patient management including transfusion support.
Introduction
Acquired bleeding disorders constitute a major proportion of laboratory referrals received in any given clinical setup, more so among hospitalized patients. The number of patients with acquired bleeding disorders far exceeds those with inherited ones. 1 Acquired bleeding disorders can occur because of platelet deficiency or dysfunction, 2 deficiency or dysfunction of coagulation factors, 3 or vascular structural abnormalities. 4 Accurate identification of the underlying cause of bleeding, whether inherited or acquired, is essential to guide further patient management. In fact, if the hospital setup is lacking advanced diagnostic facilities for inherited bleeding/coagulation disorders, then the numbers of acquired bleeding disorders may be further skewed. This article discusses the acquired bleeding disorders encountered in a tertiary care hospital setting with their underlying etiology and related management issues.
Materials and Methods
This retrospective analysis was carried out at the All India Institute of Medical Sciences, New Delhi, India, which is a tertiary care hospital having a Hematology department, having separate clinical and laboratory sections, where referrals are received from all over the country. The patients evaluated were inpatients as well as outpatients, and at times those who were referred from other hospitals in the city.
The data were tabulated from our departmental records, mainly as chart review of the laboratory requests over a 1-year period from January 1 to December 31, 2006. All the referrals of bleeding disorders received by the department were screened. Those where bleeding was diagnosed to be due to inherited causes were identified and excluded from this study. Identification of these inherited causes was done on the basis of clinical features, relevant family history (similarly affected members, consanguineous marriage), and available laboratory data. Clinical features suggesting inherited causes included early age of onset of bleeding, the nature, sites and type of bleed or history of excessive bleeding following trivial trauma, dental extraction, or minor surgical procedure from an early age. Finally, only those patients with a likely acquired cause for bleeding were selected after ensuring that there were no underlying familial/inherited bleeding disorders present. Their complete clinical and laboratory case records were tabulated and analyzed.
The laboratory testing was performed on blood samples collected from each patient in duplicate: in 3.2% trisodium citrate (1:9) for coagulation studies and 2% EDTA (1:19) vials for blood counts and peripheral smear examination.
These cases had been investigated for a coagulation workup by performing relevant laboratory tests available in our laboratory. The initial screening tests included bleeding time by template method, prothrombin time (PT), 5 activated partial thromboplastin time (APTT), 6 thrombin time (TT), 7 platelet count, and blood film inspection. Extended coagulation tests were then performed to achieve a detailed diagnosis. These included mixing studies of normal plasma with patient's plasma for screening for factor VIII inhibitors, 8 followed by Bethesda assay, 9 if the screen turned positive. If disseminated intravascular coagulation (DIC) was suspected, tests for fibrin degradation products (FDP), dimerized plasmin fragment D (D-dimer), fibrinogen levels were carried out. Euglobulin clot lysis time 10 was done to exclude primary fibrinolysis.
Bleeding time was performed by modified template method of Ivy, 11 using a 9 Â 1 mm standard template, applying 40 mm Hg pressure by a sphygmomanometer cuff (normal ¼ 2-7 minutes). Prothrombin time, APTT, and TT were performed by automated coagulometer, STA Compact, using kits and reagents by Diagnostica Stago, France. The normal ranges of values for these tests in our lab were taken as follows: PT ¼ 11 to 15 seconds, APTT ¼ 29 to 35 seconds, TT ¼ 16 to 21 seconds. Platelet count was done on a separately collected EDTA sample using a Sysmex counter XT1800i. Peripheral blood films stained by Jenner-Giemsa stain 12 were examined for platelet count and morphology (to rule out pseudothrombocytopenia) as well as to look for schistocytes among the erythrocytes (in cases of DIC) and any granulocytic cellular abnormality seen in the form of immature myeloid forms seen in myeloproliferative neoplasms (MPNs). Estimation for FDPs/D-dimers was performed using a latex agglutination kit by Diagnostica Stago. A value of D-dimer levels >0.5 mg/mL was taken as significant. The anticoagulant therapy was monitored by measuring the PT-international normalized ratio (PT-INR) 13 and APTT (H) ratio (patient vs. control) 14 for those patients who were either on oral anticoagulants (eg, Warfarin) or unfractionated heparin (UFH), respectively. For PT/INR, an INR value in the range of 2 to 3 was taken as adequately dosed for oral anticoagulants; whereas an APTT (H) ratio between 1.5 and 2.5 (patient vs. control) was considered adequately dosed for UFH.
Observations and Results
A total of 1342 reported cases of bleeding disorders were analyzed during this 1-year period (2006). Of these, 1040 cases (77.4%) had an underlying acquired cause, whereas those having an inherited cause constituted 302 cases (22.6%). The bleeding manifestations observed in these patients were largely in the form of mucocutaneous bleeds presenting as any of the following: gingival/oral bleeds, epistaxis, petechiae/purpura, ecchymosis, gastrointestinal bleeding (including nasogastric bleeds), hematuria, and menorrhagia. Bleeding from suture lines, venous access, and tracheostomy sites, as well as excessive bruising at pressure areas and intramuscular injections, were also seen. Superficial gangrene was seen only in 1 case. Besides, a significant proportion of patients presented with intracerebral bleeds and its resultant clinical picture, depending on the site of bleed.
The various causes of acquired bleeding disorders seen in our patients were DIC in 297 cases (28.5%), deranged liver functions in 218 (20.9%), neurosurgical causes (intracranial bleeds) in 154 (14.8%), cancers in 89 (8.5%), and miscellaneous causes in 282 (27.1%; Table 1 ).
The inherited causes (n ¼ 302), however, included 101 cases of platelet function defects and 201 cases of coagulation factor defects. Among the inherited platelet disorders (n ¼ 101), unclassified platelet function defects were seen in 45 cases, Glanzmann thrombasthenia in 5 cases, Bernard Soulier syndrome in 1 case, and isolated PF3 availability defect in 50 cases. The inherited coagulation disorders (n ¼ 201) included hemophilia A (n ¼ 115), hemophilia B (n ¼ 24), factor X deficiency (n ¼ 10), factor V deficiency (n ¼ 2), factor XIII deficiency (n ¼ 2), combined factor deficiency (n ¼ 3), and Von Willebrand disease (n ¼ 45). The relatively fewer number of cases of Von Willebrand disease seen in our subset is most likely due to underreporting of these cases to the hematology departments on grounds of clinical suspicion.
Among the largest subset of DIC cases (297 cases), the various underlying medical conditions (49%) such as septicemia, 15 pneumonia, and renal/ liver diseases constituted the majority. The oncological causes (16.5%) were most commonly related to hematological malignancies (AML (acute myeloid leukaemia), ALL (acute lymphoblastic leukaemia), lymphoma), whereas solid tumors such as gliomas and carcinomas of ovary, breast, gall bladder, and liver were the next most common. The acquired surgical causes (21%) of bleeding were mainly due to either road traffic accidents or following major surgeries such as laparotomies and thoracotomies. A small percentage of cases of puerperal sepsis (5%) were seen among the obstetrical and gynecological causes.
Among the patients of DIC, thrombocytopenia was seen in 46.5% patients, whereas a normal platelet count was observed in 53.5% patients. However, PT, APTT, and TT were increased in 100%, 97.8%, and 98% patients, respectively, and D-dimers were found to be elevated in 100% patients of DIC. 16 Most of these patients (>98%) belonged to the inpatients admitted in various wards.
Hepatic coagulopathy (218 cases) was seen as a result of various liver disorders 17 such as chronic hepatitis B, chronic hepatitis C, cirrhosis, acute liver failure, hepatic encephalopathy, portal hypertension, noncirrhotic portal fibrosis (NCPF), obstructive jaundice, Budd Chiari syndrome, and liver trauma. Most of these patients showed a prolonged PT as a consistent finding, with or without a prolonged APTT and thrombocytopenia. A majority of these patients were also inpatients, like the subset of DIC patients.
Acquired neurosurgical causes (154 cases) presented variously in the form of both intracranial and/or accompanying extracranial bleeding manifestations. The more common presentations of intracranial bleeds manifested in the form of either an extradural hematoma, or a subdural hematoma, or subarachnoid hemorrhage (aneurysmal bleeds involving vertebrobasilar, middle cerebral artery), intracerebral bleed/intraventricular bleed. Besides these, intracranial tumors/cysts-gliomas, meningiomas, gliosarcoma, pituitary adenoma, craniopharyngioma, third ventricular colloidal cyst, and arachnoid cyst constituted nearly 12% of neurosurgical causes of acquired bleeding. Head injury and trauma, infections such as tuberculoma, complicated malaria, herpes simplex encephalitis, SSPE (Subacute Sclerosing Pan-encephalitis), and cerebral abscess were other less common causes. Five cases of basal ganglia bleed due to systemic hypertension and 2 cases of cavernous sinus thrombosis were also seen. In a small subset of 5 cases, extracranial bleeding in the form of hematuria or epistaxis or coffee ground aspirate in nasogastric tube or along suture lines were seen in addition to intracranial bleed.
Malignancy-related acquired bleeding disorders (89 cases) were seen maximally among hematolymphoid malignancies in 46.6% cases followed by gastro intestinal tract (GIT) cancers in 40.2% cases. The remaining cases belonged to head and neck cancers constituting 6.6% and all the other cancers in 6.6% cases.
A large heterogenous subset of miscellaneous causes of bleeding (282 cases) included a variety of causes, including cases having a normal coagulation screen result. These included cases of vasculitis/ gangrene, pleuropulmonary involvement in the form of hemorrhagic pleural effusion, structural genitourinary tract bleeding such as hematuria, bleeding following major surgeries, bleeding post-massive transfusion, and post-trauma bleeding.
Acquired platelet function defects presenting with bleeding manifestations were noted in nearly 20% of MPNs studied in our department, whereas some were drug induced (aspirin, clopidogrel, captopril).
Cases of bleeding due to presence of inhibitors were also seen sporadically. Largely these patients belonged to the category of those with FVIII inhibitors seen in nearly 20% to 30% cases of hemophiliacs receiving FVIII replacement therapy, and 4 such patients were identified in our department during this 1-year period. In addition, 1 elderly patient in his seventh decade was diagnosed as a case of acquired hemophilia. Isolated prolonged PT, with or without associated bleeding manifestations, constituted a significant number of referrals (5.10%) received in the department. Such referrals were received from various specialties in the hospital, chiefly internal medicine, nephrology, obstetrics and gynecology, orthopedics, gastrosurgery/gastroenterology, hematology and trauma, and emergency medicine. In some of them, liver function tests were normal.
Age and Sex Incidence
The patients' age did not show any typical pattern of distribution because all patients had an underlying acquired cause for their bleeding manifestation. Thus, the patients' ages ranged from neonatal period, starting from few weeks to those in seventh to eighth decade of life.
Sex-wise distribution in different groups was similar, showing similar male:female ratio of nearly 2:1 in each subgroup. In DIC, 188 male (63.2%) and 109 female (36.8%) patients were seen. Liver disorders were seen in 140 males (64.2%) and 78 females (35.8%), neurosurgical causes-98 males (63.6%) and 56 females (36.4%), malignancy-related-59 males (66.2%) and 30 females (33.8%), miscellaneous-160 males (56.7%) and 122 females (43.3%). Referrals for an isolated prolonged PT was seen in 34 male (61.8%) and 21 female (38.2%) patients.
Discussion
In the current retrospective study, conducted over a 1-year period at a tertiary care referral centre at All India Institute of Medical Sciences (AIIMS), it was seen that acquired causes (77.4%) of bleeding disorders constituted a larger proportion of cases, as compared with inherited causes (22.6%). This was in accordance with similar figures quoted in worldwide literature, ranging from 75% to 85%. In fact, due to the availability of advanced diagnostic facilities for inherited bleeding disorders at our department, several inherited causes could be identified; otherwise, the figures for acquired causes could have been skewed even further.
Among the various causes, DIC was the leading cause (28.5%), followed closely by hepatic coagulopathy with an incidence of 20.9%. The other larger subsets were those due to neurosurgical causes (14.8%), mostly in the form of intracranial bleeds and bleeding disorders related to malignancy (8.5%). The larger subset of miscellaneous causes (27.1%) consisted of a variety of conditions related to bleeding, such as drug overdose (anticoagulants), acquired platelet function defects, postoperative causes, major surgeries, massive transfusions, posttrauma related, and few others that showed a normal coagulation screen.
There was no age-related distribution observed under any of these categories and the wide range of patients belonged to starting from neonates till those in the eighth decade, being same in each category. The male:female ratio was similar too in each subset, with a mean of 62.6% (range 56.7%-66.2%) for males and 37.4% (range 33.8%-43.3%) for females.
As shown in our study, there were a significant number of consultations received from various specialties for cases having an isolated prolonged PT, with or without having a bleeding manifestation. Those having bleeding could be explained by having a deranged liver function due to any cause, leading to (among other mechanisms) reduced synthesis of vitamin K-dependent coagulation factors, and was corrected after vitamin K administration as in other cases related to hepatic coagulopathy. However, a tendency to requisition fresh frozen plasma (FFP triggered by a prolonged PT > 4 seconds above control was noted among the clinicians. Segal et al 18 in an analysis of 25 studies (1 clinical trial and 24 observational studies), where invasive procedures such as bronchoscopy, central vein cannulation, angiography, liver biopsy, and paracentesis were carried out, found that bleeding rates for patients with or without abnormal coagulation test results were similar. Furthermore, Deitcher et al 19 showed that with a prolonged PT-INR in the range of 1.3 to 1.9, the factor levels of factors II, V, and VII were in the range of 31% to 65%, 40% to 70%, and 25% to 60%, respectively, which were adequate to support hemostasis. To determine the efficacy of FFP in correcting an abnormal PT, Abdel-Wahab et al 20 have shown that in 121 patients who were transfused 324 units of FFP over an INR range of 1.1 to 1.84, only 1% showed correction of PT and 15% only showed 50% correction. Stanworth 21 has reviewed the evidence that there is no evidence of benefit of FFP transfusion in a nonbleeding patient. Therefore, the recommendation for nonbleeders having a prolonged PT and INR 1.7 are that there is no need for aggressive correction measures, and this holds true for mild-to-moderate risk surgeries. 22 However, no guidelines are available for high-risk surgeries. Unwarranted FFP transfusion carries a risk of transmission of viral infections, transfusion-associated lung injury, and transfusion-associated circulatory overload. 23 However, normal screening tests for coagulation and bleeding disorders may still be obtained in certain patients who may be having any of the other underlying conditions such as senile purpura, 24 Henoch Schonlein purpura, 25 scurvy, 26 or hereditary hemorrhagic telangiectasia. 27 We thus present the spectrum of acquired bleeding encountered in a tertiary care centre in India. It is concluded that it is imperative to identify the underlying cause of acquired bleeding disorder to ensure timely institution of judicious treatment.
